VIDEX

This brand name is authorized in Estonia, Mexico, United States, South Africa

Active ingredients

The drug VIDEX contains one active pharmaceutical ingredient (API):

1 Didanosine UNII K3GDH6OH08 - DIDANOSINE

Didanosine belongs to a class of medicines called nucleoside analogues or nucleoside reversetranscriptase inhibitors (NRTIs). Intracellularly, didanosine is converted by cellular enzymes to the active metabolite, dideoxyadenosine 5'-triphosphate. Dideoxyadenosine 5'-triphosphate inhibits the activity of HIV-1 reverse transcriptase both by competing with the natural substrate, deoxyadenosine 5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation. Read about Didanosine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AF02	Didanosine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
Discover more medicines within J05AF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1160840
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 096M2001
Country: US	FDA, National Drug Code	Identifier(s): 0087-6632, 0087-6671, 0087-6672, 0087-6673, 0087-6674
Country: ZA	Health Products Regulatory Authority	Identifier(s): 36/20.2.8/0065, 36/20.2.8/0066